Dulaglutide
Also called Trulicity
Research reference
- Research amount range
- 0.75–4.5 mg per administration — not a starting amount
- Reference frequency
- Once a week — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Model accumulation timescale
- ~23.5 days — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
Dulaglutide
Evidence gap- When change was measured
- Human exposure or dose research exists for Dulaglutide, but this catalogue has no source-backed window for a visible or functional result. Pharmacokinetic or biomarker timing is not the same as outcome timing.
- When to assess
- No evidence-based reassessment point is available for this catalogue entry. Half-life or clearance time cannot be used as a proxy for when a result should appear.
- Conditions and limitations
- No source-backed special condition—such as fasting, local injection, exercise timing, or a companion compound—has been established for the claimed outcomes. Route and formulation still matter.
- When to stop
- This summary cannot supply a personal quit rule for a licensed medicine. The current product label and prescriber take precedence; severe or persistent reactions need prompt review.
No direct outcome source identified. See the compound page for evidence grading.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Key properties
- Formula
- C2646H4044N704O836S18
- Mol. weight
- 59,670.63 Da
- CAS
- 923950-08-7
External references
Vial arithmetic
Published research contexts for Dulaglutide describe 0.75–4.5 mg per administration. Descriptive only, not a recommendation.
About 4.7 days. Built as a GLP-1 analog fused to a modified IgG4 Fc fragment, which is what stretches elimination to several days and supports once-weekly dosing.
Research schedule reference
Reported schedule context for Dulaglutide; not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Starting step. | 0.75 mg | Once weekly | SubQ |
| Weeks 5+ | 1.5 mg | Once weekly | SubQ |
| After ≥4 weeks | 3 mg | Once weekly | SubQ |
| After ≥4 more weeksHighest step in AWARD-11; step up no sooner than every 4 weeks. | 4.5 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.49× single dose
- Time to steady state
- 23.5days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- AWARD-11 (Frías JP et al., Diabetes Care 2021;44:765)Once-weekly dulaglutide 3.0 mg and 4.5 mg compared with 1.5 mg over 52 weeks in adults with type-2 diabetes.